StockData
AstraZeneca PLC logo

AstraZeneca PLC (AZN) stock

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca PLC grew revenue 8.6% to $58.74B over fiscal 2025. Operating income rose 37.4% to $13.74B, moving the operating margin from 18.5% to 23.4%. Free cash flow was $11.77B, up 18.4% from a year earlier. At the latest close the market valued the company at $255.76B, 25.1 times its earnings.

Revenue
$58.74B
+8.6% vs. a year earlier
Operating income
$13.74B
+37.4% vs. a year earlier
Free cash flow
$11.77B
+18.4% vs. a year earlier
EPS, diluted
$6.54
+45.3% vs. a year earlier

Key statistics

Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026

Valuation

Market cap
$255.76B
P/E ratio
25.1
Price to sales
4.35
Price to book
5.09
Dividend yield
1.91%
Free cash flow yield
4.60%

Fundamentals

Revenue
$58.74B
Net income
$10.23B
EPS, diluted
$6.54
Free cash flow
$11.77B
Book value per share
$32.24
Diluted shares
1.56B

Trading

Previous close
$165.41
Open
$164.51
Day's range
$163.91 – $166.10
Volume
2,322,159
Average volume (20 days)
2,776,406

Market cap history

Month-end market cap since 2016, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.

PeriodAZNS&P 500DifferenceAZN per yearS&P 500 per year
1 month-1.3%+0.6%−1.9 pts
3 months-2.9%+3.4%−6.3 pts
Year to date-9.9%+13.3%−23.2 pts
1 year-2.2%+16.6%−18.8 pts
3 years+34.2%+86.4%−52.2 pts+10.3%+23.1%
5 years+50.2%+81.9%−31.7 pts+8.5%+12.7%
10 years+249.9%+318.9%−69.0 pts+13.3%+15.4%

Eleven years at a glance

Fiscal years 2015 to 2025, USD

Revenue

$58.74B+8.6% YoY

Gross profit

$48.11B+9.7% YoY

Operating income

$13.74B+37.4% YoY

Net income

$10.23B+45.3% YoY

EPS, diluted

$6.54+45.3% YoY

Free cash flow

$11.77B+18.4% YoY
Reported period

Press releases

Releases AstraZeneca filed with the SEC as exhibits to Form 8-K or 6-K

About AstraZeneca

Pharmaceutical Preparations

AstraZeneca PLC is a biopharmaceutical enterprise engaged in the discovery, development, and commercialization of therapeutic products. The organization organizes its medical pipeline across primary disease segments, notably Oncology, Cardiovascular, Renal and Metabolism (CVRM), Respiratory and Immunology, and Rare Diseases. Its investigative assets include novel molecular entities such as T-cell engagers, antibody-drug conjugates, CAR-T therapies, radioconjugates, and gene therapies. These treatments are formulated to assist healthcare professionals, clinical investigators, and patients suffering from cancer, autoimmune disorders, organ damage, and serious rare conditions.

Company profile, executives and history

AstraZeneca stock: common questions

What is AstraZeneca's stock price?

AZN closed at $163.95 on Oct 19, 2026, down 0.88% on the day.

What is AstraZeneca's market cap?

AstraZeneca was worth $255.76B at the close on Oct 19, 2026: the share price times the diluted shares outstanding.

What is AZN's P/E ratio?

AZN trades at 25.1 times earnings, based on diluted earnings per share of $6.54 over fiscal 2025.

How much revenue does AstraZeneca make?

AstraZeneca reported revenue of $58.74B for fiscal 2025, up 8.6% from a year earlier.

Does AstraZeneca pay a dividend?

Yes. AstraZeneca paid $3.13 per share over the last twelve months, a yield of 1.91% at the latest price, and has raised its annual dividend 2 years in a row.

How has AZN stock performed over the past year?

Including dividends, AZN returned -2.2% over the past year, against +16.6% for the S&P 500.

Who are AstraZeneca's competitors?

Companies most similar to AstraZeneca by business, industry and size include BMY, PFE, GSK, REGN, MRK.

See a number that looks wrong?